Found 46 Enz. Inhib. hit(s) with all data for entry = 6429 
Affinity DataKi: 380nM ΔG°: -36.6kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 400nM ΔG°: -36.5kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 450nM ΔG°: -36.2kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 470nM ΔG°: -36.1kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 480nM ΔG°: -36.1kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 590nM ΔG°: -35.6kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 620nM ΔG°: -35.4kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 700nM ΔG°: -35.1kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 720nM ΔG°: -35.1kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 850nM ΔG°: -34.6kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 950nM ΔG°: -34.4kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.01E+3nM ΔG°: -34.2kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.26E+3nM ΔG°: -33.7kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.32E+3nM ΔG°: -33.6kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.40E+3nM ΔG°: -33.4kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.42E+3nM ΔG°: -33.4kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.47E+3nM ΔG°: -33.3kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.49E+3nM ΔG°: -33.3kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.57E+3nM ΔG°: -33.1kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.58E+3nM ΔG°: -33.1kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.59E+3nM ΔG°: -33.1kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 1.93E+3nM ΔG°: -32.6kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.12E+3nM ΔG°: -32.4kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.21E+3nM ΔG°: -32.3kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.32E+3nM ΔG°: -32.2kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.59E+3nM ΔG°: -31.9kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.60E+3nM ΔG°: -31.9kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.64E+3nM ΔG°: -31.8kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.69E+3nM ΔG°: -31.8kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.82E+3nM ΔG°: -31.7kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.90E+3nM ΔG°: -31.6kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.95E+3nM ΔG°: -31.6kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 2.98E+3nM ΔG°: -31.5kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 3.06E+3nM ΔG°: -31.5kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 3.90E+3nM ΔG°: -30.9kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 3.90E+3nM ΔG°: -30.9kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 4.03E+3nM ΔG°: -30.8kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 4.11E+3nM ΔG°: -30.7kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 4.44E+3nM ΔG°: -30.6kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 4.51E+3nM ΔG°: -30.5kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 4.65E+3nM ΔG°: -30.4kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 5.16E+3nM ΔG°: -30.2kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 5.38E+3nM ΔG°: -30.1kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 5.71E+3nM ΔG°: -29.9kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 5.85E+3nM ΔG°: -29.9kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
Affinity DataKi: 8.43E+3nM ΔG°: -29.0kJ/molepH: 7.4 T: 2°CAssay Description:The compounds of the present invention inhibit the binding of PGD2 to its receptor CRTH2. The inhibitory activity can be investigated by a radioligan...More data for this Ligand-Target Pair
